Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company ProgressBusiness Wire • 03/12/26
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026Business Wire • 01/30/26
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdatesBusiness Wire • 11/05/25
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation ConferenceBusiness Wire • 10/28/25
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)Business Wire • 10/16/25
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)Business Wire • 10/07/25
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceBusiness Wire • 09/02/25
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business UpdatesBusiness Wire • 08/07/25
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth ConferenceBusiness Wire • 08/05/25
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune DiseasesBusiness Wire • 07/24/25
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare ConferenceBusiness Wire • 05/21/25
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business UpdatesBusiness Wire • 05/06/25
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences ConferenceBusiness Wire • 04/30/25
Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual MeetingBusiness Wire • 04/28/25